CUROGEN wased as one of 12 finalist companies at Investor Day Japan 2026, held March 19, 2026 in Tokyo, Japan, proudly standing as the only Korean company among the finalists in this globally competitive program.

Hosted by BioLabs GLOBAL and supported by iCONM, Astellas Pharma, and LINK-J, this prestigious event brought together leading innovators from the global life sciences community to pitch before an international audience of investors and key stakeholders.

Throughout the program, CUROGEN engaged in exclusive networking sessions with global investors, with a particularly strong presence of prominent Japanese investment firms, establishing meaningful connections that we look forward to building upon. We also participated in professional pitch seminars and training sessions, and presented our scientific vision and pipeline to the broader investment community.

This recognition as the sole Korean finalist reflects the growing global interest in CUROGEN's approach to autoimmune disease, and marks an important milestone in our journey toward becoming a globally recognized biopharmaceutical company.